Abstracts

Local and Systemic Pharmacokinetic Profile of Dapivirine Vaginal Ring-004 When Used Continuously Over Various Periods up to Twelve Weeks

Background: Dapivirine Vaginal Ring-004 (25 mg dapivirine) is a topical microbicide being evaluated for safety and efficacy in a Phase III clinical program. The pharmacokinetic (PK) profile of Ring-004 has been described for up to 35 days of continuous use. This trial investigated the PK of dapivirine from Ring-004 for continuous use up to 12…

Steady-state TDF/FTC in Genital, Rectal, and Blood Compartments in Males vs Females

Background: Despite the widespread use of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for treatment and prevention of HIV infection, gaps in knowledge remain regarding the pharmacokinetics (PK) of the intracellular active moieties, tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP), at steady-state concentrations (Css) in different compartments in the body. The purpose of this study was to describe…

Effects of Tenofovir/Emtricitabine on Endogenous Deoxyribonucleotide Pools In Vivo

Background: The potential effects of nucleoside analogs on endogenous deoxyribonucleotides (dNTP) in vivo have not been fully elucidated. The goal of this study was to characterize and quantify the effects of tenofovir-disoproxil fumarate (TDF)/emtricitabine (FTC) therapy on endogenous dNTP pools in HIV-negative and HIV-positive adults. Methods: Participants were enrolled in a pharmacokinetic study of daily…

Higher Cell Accumulation and Antiviral Activity of Lopinavir/Ritonavir Nanoparticles

Background: Using an emulsion-templated freeze-drying technique we have synthesised combination lopinavir/ritonavir (LPV/RTV) solid drug nanoparticles (SDNs) with 70% weight drug loading in the dry state and compared their antiretroviral activity and cellular accumulation in primary immune cells. Methods: MT4 cells (NIBSC, UK) and primary immune cells (CD4+ T lymphocytes, CD56+ natural killer cells, CD14+ monocytes…

HIV reservoir targeted antiretroviral nanofabrication facilitates viral clearance

Background: Limitations in adherence, toxicity and reservoir targeting underlie the needs for improvements in antiretroviral therapy (ART). We posit that long-acting nanoformulated antiretroviral therapy (nanoART) can address this need by improving current drug pharmacokinetics (PK) and biodistribution. The development of monocyte-macrophage targeting ligands could affect drug depots and target sanctuaries of viral infections. To this…

The Macrophage Proteome Defines the Long Acting Antiretroviral Therapy Cell Depot

Background: Long-acting antiretroviral therapy (nanoART) nanoformulations can improve drug adherence, reduce systemic toxicities, and facilitate clearance of human immunodeficiency virus (HIV). While, monocyte-macrophage depots of nanoART are contained in recycling and late endosomes whether these organelles provide strategic advantages for viral elimination is not known. Methods: We applied quantitative SWATH-MS proteomic and cell profiling to…

Cytoxan Enhancement of SB-728-T Engraftment: A Strategy to Improve Anti-HIV Response

Background: Administration of CCR5 modified autologous CD4 cells (SB-728-T) is safe and well-tolerated and results in increases in total CD4 counts. The modified cells traffic to lymphoid tissues and have a selective survival advantage during ART treatment interruption (TI). Studies in CCR5 Δ32 heterozygote HIV subjects showed VL reductions during TI correlated with levels of…

Highly Precise Measurements of HIV DNA in CSF and Blood by Droplet Digital PCR

Background: We investigated associations between HIV DNA reservoir dynamics in cerebrospinal fluid (CSF) and blood in subjects with or without antiretroviral therapy (ART), to better understand the dynamics of these critical targets for eradication, and to gauge how well the HIV DNA reservoir in anatomic compartments can be predicted by measurements in peripheral blood. Methods:…

Antiretroviral Concentrations in Brain Tissue Are Similar to or Exceed Those in CSF.

Background: Limited distribution of many antiretroviral therapy (ART) drugs into the central nervous system (CNS) results in much lower drug concentrations in cerebrospinal fluid (CSF) than in blood. Estimates of CSF distribution have been linked to HIV RNA levels in CSF and neurocognitive performance but results can be inconsistent. One possible reason for this inconsistency…